A Phase 2 interventional study of ABI-007 in Hemodialysis Graft Dysfunction, sponsored by Celgene. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-25.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is designed to confirm the safety of the proposed dose and schedule of ABI-007 for hemodialysis patients with vascular access device failure, and to obtain preliminary data on the effectiveness of such treatment.
This is an open-label, pilot, phase II study to assess the feasibility of administering ABI-007 intravenously [IV] over 3-5 minutes to patients with hemodialysis graft dysfunction (i.e., either a thrombosed polytetrafluoroethylene (PTFE) graft, or a patent but dysfunctional PTFE graft). Patients with graft dysfunction who are successfully treated with angioplasty will start treatment after angioplasty or during their first dialysis through the graft following intervention, and will receive 3 subsequent treatments of ABI-007 at 35 mg/m\^2 on weeks 5, 13 and 21.
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
First submitted before Celgene became part of Bristol-Myers Squibb.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ABI-007 35 mg/m\^2 given intravenously (IV) into the arteriovenous (AV) graft within 96 hours after angioplasty, followed by repeat treatment during weeks 5, 13 and 21
Drug: ABI-007
Also known as: Abraxane®, paclitaxel
Percentage of Participants With Discontinued, Delayed or Interrupted Therapy
Percentage of participants who had discontinued therapy or had a delayed dose or an interrupted (omitted) dose due to toxicities/adverse events.
Time frame: up to week 21
Percentage of Participants Without Graft Failure or Need for Intervention
Graft failure is defined as graft thrombosis, loss of vascular access function, or \>50% stenosis of the index lesion at the time of a regularly scheduled angiographic assessment.
Time frame: 24 weeks
Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Week 12
Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography.
Time frame: 12 weeks
Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Week 24
Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography.
Time frame: 24 weeks
Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Month 9
Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography.
Time frame: 9 months
Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Month 12
Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography.
Time frame: 12 months
Stenosis (%) of a Non-index Lesion Using Angiography at Week 12
Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis.
Time frame: 12 weeks
Stenosis (%) of a Non-index Lesion Using Angiography at Week 24
Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis.
Time frame: 24 weeks
Stenosis (%) of a Non-index Lesion Using Angiography at Month 9
Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis.
Time frame: 9 months
Stenosis (%) of a Non-index Lesion Using Angiography at Month 12
Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis.
Time frame: 12 months
Participants With Arthrosclerotic Cardiovascular Complications
Counts of participants who had treatment-emergent arthrosclerotic cardiovascular complications, specifically myocardial infarction, arterial thromboses, or cerebrovascular events.
Time frame: up to week 25
Kaplan Meier Estimates for Time to Graft Failure or Intervention
The time to graft failure or intervention was defined as the time from first dose of study drug to the first time graft failure or intervention. Participants who did not have graft failure or intervention at the end of the study were censored at the last known time that the participant had angiography.
Time frame: up to 12 months
Percentage of Participants With Patency of Index and Non-Index Lesions at 24 Weeks
The patency (unblocking) for index lesions is defined as \<50% of stenosis and no PFTE graft thrombosis at 24 weeks. The patency for non-index lesions is defined as \<50% of stenosis and no new non-index lesions at 24 weeks.
Time frame: 24 weeks
| Milestone | ABI-007 |
|---|---|
| Started | 9 |
| Completed | 2 |
| Not completed | 7 |
| Withdrew: Adverse event | 2 |
| Withdrew: Study cancellation | 3 |
| Withdrew: Other | 2 |
Percentage of participants who had discontinued therapy or had a delayed dose or an interrupted (omitted) dose due to toxicities/adverse events.
| percentage of participants | ABI-007 |
|---|---|
| Delayed dose | 44 |
| Interrupted | 0 |
| Discontinued therapy | 33 |
Graft failure is defined as graft thrombosis, loss of vascular access function, or \>50% stenosis of the index lesion at the time of a regularly scheduled angiographic assessment.
| percentage of participants | ABI-007 |
|---|---|
| Percentage of Participants Without Graft Failure or Need for Intervention | 0 |
Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography.
| percentage of stenosis | ABI-007 |
|---|---|
| Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Week 12 | 61.7 ± 32.51 |
Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography.
| percentage of stenosis | ABI-007 |
|---|---|
| Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Week 24 | 79.0 ± 11.40 |
Counts of participants who had treatment-emergent arthrosclerotic cardiovascular complications, specifically myocardial infarction, arterial thromboses, or cerebrovascular events.
| participants | ABI-007 |
|---|---|
| >=1 arthrosclerotic cardiovascular complication | 4 |
| Bradycardia | 1 |
| Hypotension | 1 |
| Hypertrophic obstructive cardiomyopathy | 1 |
| Carotid artery stenosis | 1 |
| Cerebrovascular accident | 1 |
| Cardiovascular disorder | 1 |
The time to graft failure or intervention was defined as the time from first dose of study drug to the first time graft failure or intervention. Participants who did not have graft failure or intervention at the end of the study were censored at the last known time that the participant had angiography.
| weeks | ABI-007 |
|---|---|
| Kaplan Meier Estimates for Time to Graft Failure or Intervention | 11.4 (11.0 to 12.0) |
The patency (unblocking) for index lesions is defined as \<50% of stenosis and no PFTE graft thrombosis at 24 weeks. The patency for non-index lesions is defined as \<50% of stenosis and no new non-index lesions at 24 weeks.
| percentage of participants | ABI-007 |
|---|---|
| Index lesion | 14 |
| Non-Index lesions | 57 |
Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography.
| percentage of stenosis | ABI-007 |
|---|---|
| Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Month 9 | 69.3 ± 4.04 |
Indexed lesion must be located in the arm and is a polytetrafluoroethylene (PTFE) thrombosed graft or a patent but dysfunctional PTFE graft with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the index lesion is measured by angiography.
| percentage of stenosis | ABI-007 |
|---|---|
| Stenosis (%) of the Index Lesion at Venous Anastomosis Using Angiography at Month 12 | 95.0 |
Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis.
| percentage of stenosis | ABI-007 |
|---|---|
| Central vein | 50.0 ± NA |
| Intragraft | 35.0 ± 35.36 |
| Arterial anastomosis | 25.0 ± NA |
Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis.
| percentage of stenosis | ABI-007 |
|---|---|
| Central vein | 40.0 ± NA |
| Intragraft | 45.0 ± 21.21 |
| Arterial anastomosis | 27.5 ± NA |
Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis.
| percentage of stenosis | ABI-007 |
|---|---|
| Central vein | 65.0 ± NA |
| Intragraft | 57.5 ± 10.61 |
| Arterial anastomosis | 25.0 ± NA |
Non-indexed lesion with a residual stenosis of less than 30% after the pre-dose angioplasty. The percent of stenosis (narrowing) of the non-index lesion is measured by angiography. Three non-index lesions are reported: central vein, intragraft and arterial anastomosis.
| percentage of stenosis | ABI-007 |
|---|---|
| Central vein | NA ± NA |
| Intragraft | 50.0 |
| Arterial anastomosis | 25.0 |
Collected over AEs collected up to 30 days after the last ABI-007 dose administration (Week 21), except for cardiovascular side effects or other events at the investigator's discretion, which would be reported whenever they occur.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABI-007 | — | 6/9 (66.7%) | 7/9 (77.8%) |
| Event | ABI-007 |
|---|---|
| Anastomotic stenosisInjury, poisoning and procedural complications | 2/9 |
| Contrast media reactionInjury, poisoning and procedural complications | 1/9 |
| Graft thrombosisInjury, poisoning and procedural complications | 1/9 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/9 |
| Cerebrovascular accidentNervous system disorders | 1/9 |
| Event | ABI-007 |
|---|---|
| Anastomotic stenosisInjury, poisoning and procedural complications | 3/9 |
| Vascular graft complicationInjury, poisoning and procedural complications | 2/9 |
| Neuropathy peripheralNervous system disorders | 2/9 |
| DiarrhoeaGastrointestinal disorders | 2/9 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/9 |
| Contrast media reactionInjury, poisoning and procedural complications | 1/9 |
| Procedural painInjury, poisoning and procedural complications | 1/9 |
| BradycardiaCardiac disorders | 1/9 |
| Cardiovascular disorderCardiac disorders | 1/9 |
| Hypertrophic obstructive cardiomyopathyCardiac disorders | 1/9 |
| Age, Continuous(years) | ABI-007 |
|---|---|
| Mean | 67.6 ± 8.16 |
| Age, Customized(participants) | ABI-007 |
|---|---|
| <65 years | 4 |
| >=65 years | 5 |
| Sex: Female, Male(Participants) | ABI-007 |
|---|---|
| Female | 6 |
| Male | 3 |
| Race/Ethnicity, Customized(participants) | ABI-007 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black of African heritage | 7 |
| White, Non-Hispanic and Non-Latino | 2 |
| White, Hispanic or Latino | 0 |
| Other | 0 |
| Weight(kg) | ABI-007 |
|---|---|
| Mean | 71.78 ± 13.271 |
Ran from Nov 2005 to primary completion in Nov 2007, 24 months.
Results were first posted in Mar 2012, 4 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albumin-Bound Paclitaxel